BPC-157 vs Cerebrolysin: Body Repair vs Brain Repair
Here is how these two compounds compare — based on published research, not marketing claims.
BPC-157
212
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
Cerebrolysin
658
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
BPC-157 and cerebrolysin are both L3 peptides with strong research profiles, but they target different organ systems. BPC-157 is a gastric pentadecapeptide studied for tissue repair throughout the body — tendons, gut, muscles. Cerebrolysin is a mixture of brain-derived neurotrophic peptides studied for neurological conditions — stroke, traumatic brain injury, dementia. One fixes the body. The other supports the brain.
Key Differences
| Attribute | BPC-157 | Cerebrolysin |
|---|---|---|
| Evidence Level | Human Trials | Human Trials |
| Category | Body Protection Compound | Neurotrophic Peptide Mixture |
| Human Data | 200+ animal studies. Two human pilot studies (2024-2025). PSI rates L3. | Hundreds of clinical publications. Phase III trials for stroke and dementia. Approved drug in many countries. PSI rates L3. |
| Safety Profile | Extensive animal safety data. Two human pilot studies. Not FDA-approved. | Approved in 40+ countries. Extensive clinical safety data from multiple trials. Generally well-tolerated. IV and IM administration. |
| Key Limitations | Most research from one group. Human data is early. | Not FDA-approved. Multi-component mixture makes mechanistic study difficult. Some trials showed modest effect sizes. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
BPC-157
Promotes angiogenesis and growth factor expression at injury sites. Targets tissue repair through vascular regeneration and nitric oxide modulation.
Cerebrolysin
A standardized mixture of low-molecular-weight neuropeptides and amino acids derived from porcine brain tissue. Contains fragments that mimic BDNF, NGF, GDNF, and CNTF — the brain's own growth and repair factors.
Different targets, different biology. BPC-157 targets vascular repair and growth factor signaling in peripheral tissues. Cerebrolysin targets neurotrophic pathways in the brain. BPC-157 rebuilds blood supply to injured tissue. Cerebrolysin provides the growth factors that damaged neurons need to survive and reconnect.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 870 indexed studies. Here are the key findings.
Both L3, but with different evidence profiles. Cerebrolysin has more human clinical data — hundreds of publications and regulatory approval in 40+ countries. BPC-157 has more total preclinical studies but less clinical depth. For the brain, cerebrolysin is better validated. For the body, BPC-157 has more relevant data.
For neurological conditions (stroke, TBI, dementia), cerebrolysin has extensive clinical data.
For tissue repair (tendon, gut, muscle), BPC-157 has more relevant research.
For neuroprotection specifically, cerebrolysin is the established option.
They are not interchangeable — different organ systems, different applications.
Key Limitations
- •No head-to-head comparison.
- •They target different organ systems, limiting direct comparison.
- •BPC-157's neuroprotective data is preliminary compared to cerebrolysin's.
- •Cerebrolysin's multi-component nature makes precise mechanistic comparison difficult.
PSI Verdict
SUPPORTED BY EVIDENCE
BPC-157 promotes tissue repair through angiogenesis in over 200 preclinical studies with emerging human data. Cerebrolysin improves neurological outcomes in stroke and TBI patients across multiple clinical trials, with regulatory approval in 40+ countries.
NOT YET ESTABLISHED
BPC-157's neuroprotective effects, while observed in animals, are not validated at the clinical level cerebrolysin has achieved. Whether combining them for combined peripheral and central nervous system repair is beneficial is unknown.
CONFIDENCE LEVEL
High within their respective domains. Cerebrolysin for the brain. BPC-157 for the body. Both L3, both well-researched, both serving different purposes.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"Insufficient evidence
Cerebrolysin
"Cerebrolysin is used in hospitals across Europe and Asia"Supported by evidence
"Cerebrolysin improved my cognitive function after brain injury"Plausible — clinical data exists
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
BPC-157
Extensive animal safety data. Two human pilot studies. Not FDA-approved.
Cerebrolysin
Approved in 40+ countries. Extensive clinical safety data from multiple trials. Generally well-tolerated. IV and IM administration.
Cerebrolysin has significantly more clinical safety data from its decades of regulated use. BPC-157 has extensive animal safety data and early human data. Both appear well-tolerated within their research contexts.
WHAT THE RESEARCH SUGGESTS
Different specialties. BPC-157 for body repair. Cerebrolysin for brain repair. Comparing them is useful only for understanding which tool serves which goal.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.